At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 220 enrolled
Drug / intervention
pregabalindrug
Likely dose
pregabalin 75mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Extension Safety And Efficacy Trial Of Pregabalin In Subjects With Neuropathic Pain Associated With Human Immunodeficiency Virus (HIV) Neuropathy
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·interventional·Posted Dec 13, 2005·Updated Jan 22, 2021
In Brief
A Phase 3 clinical trial evaluating pregabalin for Peripheral Neuropathy and HIV Infections. Completed, enrolled 220 participants across 37 sites in 2 countries.
Detailed Summary
To evaluate the safety and efficacy of pregabalin in reducing neuropathic pain associated with HIV neuropathy
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeripheral Neuropathy, HIV Infections
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 2005
Enrollment StartFeb 2006
Primary CompletionFeb 2008
TodayJul 2026
First PostedDec 13, 2005
Enrollment StartFeb 1, 2006
Primary CompletionFeb 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 20.6 years ago
Interventions
pregabalindrug
75mg BID, titrated up to 300mg according to individual response and tolerability